AZA + Venetoclax as Maintenance Therapy in Patients With AML in Remission

NCT04062266 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

50

Enrollment

OTHER

Sponsor class

Conditions

Acute Myeloid Leukemia in Remission
FLT3 Gene Mutation
Hematologic and Lymphocytic Disorder
Acute Myeloid Leukemia
Minimal Residual Disease Persistence
Therapy-Related Acute Myeloid Leukemia

Interventions

DRUG: Azacitidine
DRUG: Venetoclax

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]
[object Object]